Reata Pharmaceuticals (RETA) is a clinical-stage biotechnology company specializing in drugs that affect mitochondria-related diseases. Its lead candidate is for PAH (pulmonary arterial hypertension) resulting from connective tissue disease.
Reata came up in a screening I did of the new additions to the Nasdaq Biotechnology Index, which is used as a basis for the iShares Nasdaq Biotechnology ETF (IBB). If you want to pick individual stocks and try to beat the IBB, the understanding the component companies is a good place to start.
However, keep in mind that beating the IBB by investing in individual biotech stocks is not easy, even for experienced stock pickers. It takes a lot of time to research stocks. If I did not have the time, I would be happy just to own the IBB or SPDR S&P Biotech ETF (XBI), or both. For the complete list of adds, see Nasdaq Biotech Index: 54 to be added. I wrote about the first stock from my screen in Endocyte, Now Included In IBB, Has A Strong Clinical-Stage Asset.
Top Biotech Stocks To Watch For 2019: Autohome Inc.(ATHM)
Advisors' Opinion:- [By Logan Wallace]
Autohome (NYSE:ATHM) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Wednesday.
- [By Joseph Griffin]
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
Get Autohome alerts: Dow Jones Falls Before Trump’s Iran Decision; These 2 IBD 50 Stocks Jump (investors.com) Autohome Quarterly Earnings Beat Estimates, Guides Higher (finance.yahoo.com) Autohome (ATHM) Posts Earnings Results, Beats Expectations By $0.11 EPS (americanbankingnews.com) Earnings Reaction History: Autohome Inc., 44.4% Follow-Through Indicator, 4.6% Sensitive (nasdaq.com) BRIEF-Autohome Reports Qtrly Earnings Per Share Of RMB 4.05 (reuters.com)Several analysts have recently commented on the stock. ValuEngine raised shares of Autohome from a “hold” rating to a “buy” rating in a research report on Wednesday, April 11th. Zacks Investment Research raised shares of Autohome from a “hold” rating to a “buy” rating and set a $99.00 price objective for the company in a research report on Monday, March 12th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $73.97.
- [By Ethan Ryder]
Raymond James & Associates reduced its stake in shares of Autohome Inc (NYSE:ATHM) by 3.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 229,347 shares of the information services provider’s stock after selling 7,721 shares during the quarter. Raymond James & Associates owned 0.19% of Autohome worth $23,164,000 at the end of the most recent quarter.
- [By Leo Sun]
Tencent's and JD's investments in Bitauto, which date back over three years, allow the two companies to expand their ecosystems into the online automotive market. By tethering itself to Tencent's WeChat and JD's online marketplace, Bitauto widens its moat against Autohome (NYSE:ATHM), its primary rival.
- [By Max Byerly]
Autohome (NYSE: ATHM) and Pegasystems (NASDAQ:PEGA) are both computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings.
- [By Stephan Byrd]
Autohome Inc (NYSE:ATHM)’s share price fell 6.5% during trading on Friday . The stock traded as low as $76.95 and last traded at $77.41. 1,384,400 shares were traded during trading, an increase of 64% from the average session volume of 842,765 shares. The stock had previously closed at $82.76.
Top Biotech Stocks To Watch For 2019: Shire plc(SHPG)
Advisors' Opinion:- [By Lisa Levin] Gainers Sanmina Corp (NASDAQ: SANM) shares rose 15.2 percent to $31.90 in pre-market trading as the company reported stronger-than-expected earnings for its second quarter on Monday. Cadence Design Systems, Inc. (NASDAQ: CDNS) rose 12.4 percent to $41.30 in pre-market trading after the company posted upbeat Q1 results and issued a strong Q2 forecast. Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) rose 10.8 percent to $8.75 in pre-market trading. Mitel Networks Corporation (NASDAQ: MITL) rose 8.8 percent to $11.05 in pre-market trading after the company agreed to be acquired by affiliates of Searchlight Capital Partners for $2.0 billion. Galectin Therapeutics, Inc. (NASDAQ: GALT) rose 7.3 percent to $3.70 in pre-market trading. Riot Blockchain, Inc. (NASDAQ: RIOT) shares rose 6.9 percent to $7.00 in pre-market trading after declining 1.50 percent on Monday. Hallmark Financial Services, Inc. (NASDAQ: HALL) rose 6.5 percent to $10.68 in pre-market trading. Boot Barn Holdings, Inc. (NYSE: BOOT) rose 5.2 percent to $20.40 in pre-market trading after gaining 4.53 percent on Monday. New Oriental Education & Technology Group Inc. (NYSE: EDU) rose 5 percent to $91.16 in pre-market trading after reporting Q3 results. Shire plc (NASDAQ: SHPG) rose 5 percent to $167.98 in pre-market trading after Bloomberg reported that Takeda is nearing a preliminary agreement to acquire Shire after sweetened bid. Outfront Media Inc. (NYSE: OUT) shares rose 5 percent to $19.00 in pre-market trading. Geron Corporation (NASDAQ: GERN) rose 4.3 percent to $4.18 in pre-market trading after gaining 5.80 percent on Monday. SAP SE (NYSE: SAP) rose 3.7 percent to $109.80 in pre-market trading after the company posted strong quarterly results and raised its outlook for the year. Golden Ocean Group Limited (NASDAQ: GOGL) shares rose 3.7 percent to $8.70 in pre-market trading after gaining 1.45 percent on Monday. Deutsche Bank Aktiengesellschaft (NYSE: D
- [By Alexander Bird]
Headquartered in Dublin, Ireland, Shire Plc. (Nasdaq: SHPG) is an international biotech firm that specializes in developing treatments for rare diseases and chronic conditions.
- [By Keith Speights]
Two other biotech stocks also turned in great performances this week -- Shire plc (NASDAQ:SHPG) and Vital Therapies (NASDAQ:VTL). But are Allena, Shire, and Vital Therapies smart picks for investors after this week's big gains?
- [By Benzinga News Desk]
Takeda Pharmaceutical Co. on Tuesday reached an agreement to buy Shire PLC (NASDAQ: SHPG), capping a months long battle for control of the European drugmaker and marking the biggest-ever overseas acquisition by a Japanese company: Link $
- [By Todd Campbell]
Takeda Pharmaceutical Co. (NASDAQOTH:TKPYY) announced late last month its interest in making an offer to acquire Shire (NASDAQ:SHPG), and according to Shire, Takeda has followed through with three separate bids. So far, Shire's board of directors has rejected the offers as inadequate, but that doesn't mean another offer won't convince them otherwise. It's unclear if Takeda will make yet another bid, or when it might do so. But even if it doesn't, a deal could still be struck.
Top Biotech Stocks To Watch For 2019: ESSA Pharma Inc.(EPIX)
Advisors' Opinion:- [By Stephan Byrd]
Get a free copy of the Zacks research report on ESSA Pharma (EPIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Get a free copy of the Zacks research report on ESSA Pharma (EPIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Avid Bioservices (NASDAQ:CDMO) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.
No comments:
Post a Comment